Target intelligence / Profile preview

5-oxoprolinase (ATP-hydrolysing) (OPLAH)

Target
OPLAH
Molecular classification
Enzyme, Hydrolase (specifically acting on carbon-nitrogen bonds in cyclic amides)
01

Overview

5-oxoprolinase (ATP-hydrolysing), commonly abbreviated as OPLAH, is an enzyme that acts as a homodimer and uses ATP hydrolysis to catalyze the conversion of 5-oxo-L-proline to L-glutamate, a crucial step in the gamma-glutamyl cycle and essential for glutathione biosynthesis. This enzyme is a member of the hydrolase family, specifically those acting on carbon-nitrogen bonds in cyclic amides. Genetic defects in OPLAH lead to 5-oxoprolinase deficiency (OPLAHD), an inborn error of metabolism characterized by elevated 5-oxoproline and can result in metabolic acidosis. OPLAH plays an important role in intracellular cysteine delivery and protection against cysteine toxicity by maintaining glutathione homeostasis. While it has significant biochemical and disease associations, no approved drugs directly target OPLAH, but its function can be modulated through substrate analogs that increase glutathione synthesis.

Other names
5-OPase5-oxo-L-prolinaseOPLAOPLAHD5-OPASEPyroglutamaseoxoprolinasepyroglutamate hydrolasepyroglutamic hydrolaseL-pyroglutamate hydrolase
02

Mechanism of action

Substrate analogs such as L-2-oxothiazolidine-4-carboxylate are metabolized by 5-oxoprolinase to enhance glutathione production

03

Biological functions

Catalyzes conversion of 5-oxo-L-proline to L-glutamateParticipates in glutathione metabolism (gamma-glutamyl cycle)Involved in intracellular cysteine delivery and protection against cysteine toxicity
04

Disease associations

5-oxoprolinase deficiency (OPLAHD)Glutathione synthetase deficiency
05

Safety considerations

Genetic deficiency causes 5-oxoprolinase deficiency, leading to accumulation of 5-oxoproline and metabolic acidosisTherapeutic modulation may risk altering glutathione metabolism and redox balance
06

Interacting drugs

L-2-oxothiazolidine-4-carboxylate
07

Biomarkers

Mutations or activity of OPLAH can serve as a marker for 5-oxoprolinase deficiency and related inborn errors of metabolismNot widely used as a biomarker in standard clinical practice

Beyond the preview

Go deeper on 5-oxoprolinase (ATP-hydrolysing) (OPLAH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-oxoprolinase (ATP-hydrolysing) (OPLAH).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call